The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees
19.1.2026 09:00:00 CET | Business Wire | Press Release
Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/
Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit
With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold. The top hit is announced today, Blue Monday, to help people get through the most depressing day of the year.
The 1970 chart topper held off stiff competition from Stand By Me by Ben E King with 5.7% of the vote and Imagine by John Lennon with 5.3%.
Hope on Repeat in support of refugees
UK for UNHCR’s winter campaign ― Hope on Repeat ― aims to highlight the experiences of refugees around the world, with a specific focus on families from Afghanistan, Syria and Ukraine who will spend the winter forcibly displaced from their homes.
Music is widely seen as a universal language and a sign of solidarity. UK for UNHCR has worked with Royal College of Music academic, Norbert Meyn, to explore how music drives connection and empathy ― while a UK for UNHCR survey* shows that 73% of us believe that music unites people.
Hope on Repeat guest, Bosnian public speaker and researcher, Smajo OBE, said, “I was welcomed with open arms to the UK and Newcastle in 1994. At first, I felt out of place. But one song changed everything. My classmates and teacher sang it in Bosnian to make me feel at home.”
The Hope on Repeat campaign also features a series of five podcasts hosted by British poet, Sophia Thakur, that share the incredible stories of people forced to flee their homes ― named The Guardian’s podcast of the week. The Hope on Repeat podcast is available from www.unrefugees.org.uk/hope
Hope on Repeat guest, Ukrainian film director and producer, Mariia, said, “No matter the language, music has the power to make people feel something. It conveys the basic emotions of humanity.”
Visit unrefugees.org.uk/hope to find out what Mariia and Smajo's Hope Hits are and the stories behind them, and how you can support refugees this winter.
Editors Notes
For the latest statistics and reports, please visit UNHCR’s Operational Data Portal here. https://data.unhcr.org/
The video is available here: https://youtu.be/rTKO7zmChE0
Winning song graphic – here
Refugee Storyteller images – here
Hero video footage - YouTube / MP4
1148 people voted for their Hope Hit between 10 November 2025 and 13 January 2026.
About the survey
The UK for UNHCR-commissioned Censuswide survey questioned over 2,000 people from across England, Northern Ireland, Scotland and Wales in November 2025. Responses form a snapshot of UK attitudes to music’s role in building better cultural understanding and strengthening communities in 2025.
About UK for UNHCR
UK for UNHCR is the UN Refugee Agency’s national charity partner for the UK. We build solidarity, create partnerships and raise funds across the UK to help deliver global humanitarian relief for refugees through UNHCR’s work. unrefugees.org.uk
UNHCR, the UN Refugee Agency, leads international action to protect people forced to flee their homes because of conflict and persecution. It delivers lifesaving assistance like shelter, food and water, helps safeguard fundamental human rights and develops solutions that ensure people have a safe place to call home where they can build a better future. UNHCR also works to ensure that stateless people are granted a nationality. www.unhcr.org
UK for UNHCR is a registered charity in England and Wales (registered charity number 1183415).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260119165712/en/
Contacts
For media enquiries, please contact:
Sanjiv Winayak | sanjiv@milkandhoneypr.com | +44 (0)777 336 270
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom